Insulin degludec

Active ingredient description

Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
A10AE06 A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AE Insulins and analogues for injection, long-acting
Discover more medicines within A10AE06

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
TRESIBA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
TRESIBA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

External identifiers

CAS Substance: 844439-96-9
DrugBank Drug: DB09564
KEGG Drug: D09727
RxNorm Ingredient: 1670007
SNOMED-CT Concept: 710281005
Insulin degludec (substance)
UNII Identifier: 54Q18076QB
INSULIN DEGLUDEC

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.